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Abstract
Neonatal pulmonary vascular disease (PVD) is increasingly recognized as a
disease that complicates the cardiopulmonary adaptations after birth and pre-
disposes to long-term cardiopulmonary disease. There is growing evidence
that PVD is associated with disruptions in the nitric oxide (NO)-cGMP-phos-
phodiesterase 5 (PDE5) pathway. Examination of the functionality of different
parts of this pathway is required for better understanding of the pathogenesis
of neonatal PVD. For this purpose, the role of the NO-cGMP-PDE5 pathway
in regulation of pulmonary vascular function was investigated in vivo, both at
rest and during exercise, and in isolated pulmonary small arteries in vitro, in
a neonatal swine model with hypoxia-induced PVD. Endothelium-dependent
vasodilatation was impaired in piglets with hypoxia-induced PVD both
in vivo at rest and in vitro. Moreover, the responsiveness to the NO-donor
SNP was reduced in hypoxia-exposed piglets in vivo, while the relaxation to
SNP and 8-bromo-cyclicGMP in vitro were unaltered. Finally, PDE5 inhibi-
tion-induced pulmonary vasodilatation was impaired in hypoxia-exposed pig-
lets both in vitro and in vivo at rest. During exercise, however, the pulmonary
vasodilator effect of PDE5 inhibition was significantly larger in hypoxia-
exposed as compared to normoxia-exposed piglets. In conclusion, the
impaired endothelium-dependent vasodilatation in piglets with hypoxia-
induced PVD was accompanied by reduced responsiveness to NO, potentially
caused by altered sensitivity and/or activity of soluble guanylyl cyclase (sGC),
resulting in an impaired cGMP production. Our findings in a newborn animal
model for neonatal PVD suggests that sGC stimulators/activators may be a
novel treatment strategy to alleviate neonatal PVD.
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Introduction
Dysmorphic pulmonary vascular growth and impaired
alveolarization are hallmarks of the disruption of normal
lung development that characterizes bronchopulmonary
dysplasia (BPD) (Jobe 1999; Coalson 2003; Mourani and
Abman 2013). Pulmonary vascular disease (PVD) encom-
passes decreased angiogenesis, abnormal vascular function
with increased vasomotor tone and altered vasoreactivity,
and abnormal vascular structure (vascular remodeling)
with smooth muscle cell proliferation. These changes
result in an increased pulmonary vascular resistance
(PVR), thereby increasing the risk of pulmonary hyper-
tension (PH) in BPD patients (Jobe 1999; Coalson 2003;
Mourani and Abman 2013; Rossor and Greenough 2015).
Retrospective studies have determined the incidence of
BPD-associated PH to be approximately 20–40% (Khe-
mani et al. 2007; An et al. 2010; Slaughter et al. 2011;
Weismann et al. 2017). Although most studies concerning
long-term outcome of BPD focus on respiratory function,
there is increasing awareness that PVD (including PH)
imposes additional morbidity, including prolonged oxy-
gen requirements and exercise intolerance, and mortality
in the already vulnerable BPD infants (Khemani et al.
2007; Slaughter et al. 2011). Therapies currently used in
clinical practice for infants with PVD are supplemental
oxygen therapy to avoid hypoxic pulmonary vasoconstric-
tion (Berkelhamer et al. 2013b; Rossor and Greenough
2015), pulmonary vasodilators such as sildenafil (phos-
phodiesterase 5 inhibitor) and inhaled nitric oxide (iNO)
(Berkelhamer et al. 2013b; Rossor and Greenough 2015),
that may also limit oxidative stress caused by hyperoxia
(Berkelhamer et al. 2013a; de Wijs-Meijler et al. 2017a),
However, the knowledge regarding treatment efficacy and
safety of BPD-associated PH is limited and needs to be
further investigated.
Previous studies in swine showed an important role for
the nitric oxide (NO)-cGMP signaling pathway in the
pathogenesis of chronic PH (Fike et al. 1998; Fike et al.
2004). Nitric oxide (NO) is produced in the vascular
endothelial cells from L-arginine by the enzyme endothe-
lial nitric oxide synthase (eNOS), and then diffuses to the
vascular smooth muscle cell. There, NO stimulates soluble
guanylyl cyclase (sGC), resulting in the production of
cGMP, which activates cGMP-dependent protein kinases.
Ultimately, this leads to opening of the large conductance
K (BKCa) channel, smooth muscle cell relaxation and thus
vasodilatation (McDonald and Murad 1995). There is
growing evidence that neonatal pulmonary hypertension
is associated with multiple disruptions in this signaling
cascade. A decreased eNOS activity and reduced vasodila-
tor response to NO were found in different animal mod-
els for neonatal PH (North et al. 1995; Shaul et al. 1997;
Tulloh et al. 1997; Fike et al. 1998, 2004; Berkenbosch
et al. 2000). There are, however, only a few studies
regarding the role of more downstream disruptions in the
NO-cGMP signaling pathway, including sGC -and cGMP-
dependent mechanisms (Steinhorn et al. 1995; Tulloh
et al. 1997; Berkenbosch et al. 2000). Furthermore, no
studies were performed to assess the long-term conse-
quences of disruptions in the NO-cGMP signaling path-
way. Therefore, examination of the functionality of
different parts of this pathway is required for better
understanding of the pathogenesis of BPD-associated PH,
not only in the neonatal period but also later in life.
We previously developed a neonatal swine model with
hypoxia-induced PH showing the clinical features resem-
bling those found in patient with neonatal PVD and/or
PH, in terms of pulmonary hemodynamics, abnormalities
in the structure of the right ventricle and disruptions in
normal lung development (vascular remodeling) (de
Wijs-Meijler et al. 2017c). This model allows 3-weeks of
follow-up after re-exposure to normoxia with hemody-
namic measurement at rest and during exercise in awake
piglets. By placing the cardiopulmonary system under
stress with exercise testing, subtle dynamic abnormalities
that are not apparent on conventional static tests may be
revealed. Additionally, exercise testing helps to assess the
severity of the disease. Consequently, the main purpose of
this study was to determine the functionality of different
parts of the NO-cGMP signaling pathway in the long-
term, in vivo (at rest and during incremental exercise)
and in vitro, to achieve greater understanding of the
pathogenesis of neonatal PH associated with BPD (or
other chronic cardiopulmonary disorders associated with
hypoxia) and the long-term sequela of damage to the
developing neonatal lung.
Methods
Ethical approval
Studies were performed in accordance with European
Directive 2010/63/EU as well as with the “Guiding Princi-
ples in the Care and Use of Laboratory Animals” as
approved by the Council of the American Physiological
Society, and with approval of the Animal Care Committee
of the Erasmus MC Rotterdam (Protocolnumber 109-12-
11, EMC 2702).
In vivo animal experiments
Thirty-four crossbred Landrace x Yorkshire piglets of
either sex entered the study when they were 48 h old.
Shortly after arrival, all piglets received a single dose of
artificial colostrum (Colo-active) and were placed in an
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incubator, in which the fraction of inspired oxygen
(FiO2) can be regulated, for 4 weeks. Piglets assigned to
the control group were exposed to a normobaric nor-
moxic environment (FiO2 21%; N = 16), whereas piglets
assigned to the intervention group were exposed to a nor-
mobaric hypoxic environment (N = 18). Piglets in the
Hypoxia group were exposed to FiO2 10% for at least
1 week, and FiO2 was adjusted to higher levels (max.
FiO2 12%) based on clinical signs of severe pulmonary
hypertension (severe dyspnea, growth retardation, septal
shift on echocardiography). Piglets were fed age appropri-
ately (Lactowean Extra, Babywean, Topwean; Denkavit,
Voorthuizen, The Netherlands) and received a supple-
mentary feed for piglets, based on egg yolk (MS Pig
Pusher Oral, Schippers BV, Bladel, The Netherlands) from
day 1–3, to support the immune system and to increase
the vitality of the newborn piglets, especially in case of
insufficient colostrum. They were weighed daily.
After 4 weeks in the incubator, piglets were chronically
instrumented as described below, and subsequently placed
in a normoxic environment. A schematic representation
of the methods is presented in Figure 1.
Surgical procedures
Piglets were sedated with tiletamine/zolazepam (3 mg kg1
i.v.), xylazine (1.75 mg kg1 i.v.), and atropine (0.5 mg),
intubated and ventilated with a mixture of O2 and N2
(1:2) to which 2.0% (v/v) isoflurane was added for ade-
quate anesthesia. The depth of anesthesia was checked
regularly using a pain stimulus (toe-pinch). Due to pre-
mature death, caused by health problems related to expo-
sure to hypoxia (N = 6), only 28 piglets (Normoxia,
N = 16;, Hypoxia N = 12) were instrumented under ster-
ile conditions as previously described (De Wijs-Meijler
et al. 2016). Briefly, the chest was opened via the fourth
left intercostal space and fluid-filled polyvinylchloride
catheters were inserted into the aortic arch, pulmonary
artery, left atrium, and right ventricle for pressure mea-
surements. Furthermore, these catheters were used for
blood sampling as well as for the infusion of drugs. In a
subset of animals (N = 13), a flow probe (14–16 mm,
Transonic Systems) was positioned around the pulmonary
artery for measurement of cardiac output. Catheters and
electrical wires were tunnelled subcutaneously to the back
and the chest was closed in layers. All animals were
placed in a normoxic environment and were allowed to
recover, receiving analgesia (Buprenorphine 0.015
mg kg1 i.m., Fentanyl slow-release patch 6 lg h1) and
antibiotic prophylaxis (Augmentin 25/5 mg kg1 i.v.) for
7 days. The catheters were flushed daily with heparinized
saline (1000–5000 IE mL1). Five piglets died during or
shortly after surgery, and four piglets were not able to
perform exercise experiments due to limb infection.
Figure 1. Schematic representation of the experimental design of the study.
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Finally, 19 piglets (Normoxia, N = 10 (six female, four
male); Hypoxia, N = 9 (five female, four male)) were
included for analysis.
Experimental protocols; agonist-induced
vasodilatation
Studies were performed 10  1 days after surgery in both
groups. Fluid-filled pressure transducers were positioned
on the back of the animals and calibrated at midchest
level. Baseline hemodynamic measurements were obtained
in resting piglets (Normoxia, N = 8 (six female, two
male); Hypoxia, N = 8 (four female, four male)), consist-
ing of heart rate, cardiac output (CO), aortic pressure
(MAP), pulmonary artery pressure (PAP), left atrial pres-
sure (LAP), and right ventricular pressure (RVP). To
study the responsiveness of the vascular beds to nitric
oxide (NO), we determined the hemodynamic responses
to the endothelium-independent exogenous NO-donor
sodium nitroprusside (SNP; 0.5–5 lg kg1 min1, i.v.) in
resting swine.
Experimental protocols; exercise
experiments
Control exercise trials were performed 9  1 days after
surgery in both groups with piglets exercising on a
motor-driven treadmill. Fluid-filled pressure transducers
were positioned on the back of the animals and calibrated
at midchest level. With piglets (Normoxia, N = 10 (six
female, four male); Hypoxia, N = 9 (five female, four
male)) standing on the treadmill, resting hemodynamic
measurements, consisting of heart rate, cardiac output
(CO), MAP, PAP, LAP, and RVP were obtained. Rectal
temperature was measured, and arterial and mixed venous
blood samples were collected. Subsequently, a four-stage
treadmill exercise protocol was started (1–4 km h1);
each exercise stage lasted 3 min. Hemodynamic parame-
ters were continuously recorded and blood samples were
collected during the last 45 sec of each exercise stage, at a
time when hemodynamics had reached a steady state (De
Wijs-Meijler et al. 2016). After completing the exercise
protocol, animals were allowed to rest on the treadmill.
After 90 min of rest, two different protocols (see below)
were performed in a subset of swine, on different days
and in random order. The number of swine in each pro-
tocol, as well as overlap between protocols, are shown in
Table 1. Excellent reproducibility of consecutive exercise
trials has been reported previously (Duncker et al. 2000).
Ninety minutes after piglets had undergone a control
exercise trial (as described above) the NO-synthase
inhibitor Nx-nitro-L-Arginine (LNNA, Sigma) was
administered at a dose of 20 mg kg1 i.v. in nine
normoxia-exposed (six female, three male, 19  1 days
after surgery) and eight hypoxia-exposed (five female,
three male, 18  1 days after surgery and re-exposure to
normoxia) piglets. Ten minutes after completion of the
infusion, resting measurements were obtained and the
four-stage exercise protocol was repeated (Houweling
et al. 2005).
On a different day (16  2 days after surgery for
normoxia animals and 14  1 days after surgery and
re-exposure to normoxia for the hypoxia-exposed animals),
the exercise protocol was repeated, but during the second
exercise protocol the phosphodiesterase-5 (PDE5) inhibitor
EMD360527 (a gift from Merck, Darmstadt, Germany) was
infused continuously in a dose of 300 lg kg1 min1 i.v.
in six normoxia-exposed (two female, four male) and five
hypoxia-exposed (three female, two male) piglets. Ten
minutes after starting the infusion, resting measurements
were obtained and the four-stage exercise protocol was per-
formed (Houweling et al. 2012; Zhou et al. 2014).
In vitro myograph experiments
At the end of the study (4–6 weeks after re-exposure to
normoxia), all piglets (Normoxia, N = 10; Hypoxia,
N = 9) were reanesthetized and killed by inducing cardiac
arrest using electromechanical dissociation of the heart.
Right lungs were immediately excised and pulmonary
small arteries (diameter  300 lm) were dissected out
from the lower lung lobe and stored overnight placed in
cold, oxygenated Krebs bicarbonate solution of the fol-
lowing composition (in mmol/L): NaCl 118, KCl 4.7,
CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and
glucose 8.3; pH 7.4. The next day, pulmonary small arter-
ies were cut into segments of ~2 mm length and mounted
in microvascular myographs (Danish MyoTechnology)
with separated 6 mL organ baths containing Krebs bicar-
bonate solution aerated with 95% O2-5% CO2 and main-
tained at 37 ̊ C (Mulvany and Halpern 1977). Changes in
contractile force were recorded with a Harvard isometric
transducer. Following a 30-min stabilization period, a
Table 1. Schematic representation of the overlap of swine used
in the different protocols.
Control LNNA EMD360527 Total
Control 10N/9H 9N/8H 6N/5H
LNNA 9N/8H 6N/5H
EMD360527 - 6N/5H
Total 10N/9H
Bold font indicates the total number of swine in each experimen-
tal protocol.
N, normoxia; H, hypoxia.
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length-tension curve was constructed and the internal
diameter of the pulmonary small arteries was set to a ten-
sion equivalent to 0.9 times the estimated diameter at
20 mmHg effective transmural pressure. Vessels were then
exposed to 30 mmol/L KCl twice. Endothelial integrity of
pulmonary arteries was verified by observing dilation to
10 nmol/L substance P after precontraction with
100 nmol/L of the stable thromboxane A2 analogue pyri-
doxalphophate-6-azophenyl-2040-disulfonic acid (U46619).
If no vasorelaxation to substance P was observed, the ves-
sel segment was excluded from further study. Then vessels
were subjected to 100 mmol/L KCl to determine the max-
imal vascular contraction (Mulvany and Halpern 1977).
Thereafter, pulmonary arteries were allowed to equilibrate
in fresh Krebs solution for 30 min, before initiating dif-
ferent experimental protocols (Zhou et al. 2014).
Response to vasoactive substances in vitro
After 30 min of equilibration in fresh Krebs, pulmonary
small arteries were precontracted with 100 nmol/L
U46619 before starting with one of five different experi-
mental protocols (Zhou et al. 2014). Only one protocol
was executed per vessel segment and within one protocol,
all vessels were obtained from different animals.
In a first set of segments (Normoxia, N = 5 (3 female, 2
male); Hypoxia, N = 8 (4 female, 4 male)), endothelium-
dependent vasodilatation to bradykinin (BK; 1010–106.5
mol/L; Sigma-Aldrich, Zwijndrecht, The Netherlands) was
recorded. Concentration-response curves (CRC) to the PDE-
5 inhibitor sildenafil (1010–105 mol/L; Sigma-Aldrich)
were constructed from a second set of segments (Normoxia,
N = 6 (four female, two male); Hypoxia, N = 8 (four female,
four male)). To study whether responses to endothelium-
independent but NO-mediated vasodilatation were altered by
transient exposure to chronic hypoxia, CRCs to exogenous
NO-donor sodium nitroprusside (SNP; 109–106 mol/L;
Sigma-Adrich) were examined (Normoxia, N = 9 (six
female, three male); Hypoxia, N = 8 (four female, four
male)). Finally, separate vessels segments were studied to
determine whether impairments in smooth muscle cell
relaxation to the NO second messenger, cyclic GMP, were
involved in altered responses to SNP. For these studies,
CRCs to 8-bromo-cyclic GMP (107–103.5 mol/L) were
measured (Normoxia, N = 8 (five female, three male);
Hypoxia, N = 8 (four female, four male)).
Data analysis and statistical analysis
Digital recording and off-line analysis of hemodynamics
have been described previously (Stubenitsky et al. 1998).
Pulmonary vascular conductance (PVC) was defined as
CO divided by PAP minus LAP (Merkus et al. 2008).
Systemic vascular conductance (SVC) was calculated as
the ratio of CO and MAP. To accommodate for the vary-
ing weights between animals and groups, CO, PVC, and
SVC were indexed to body weight. Statistical analysis was
performed using SPSS version 21.0 (IBM, Armonk, NY).
To test whether the effect of drug intervention (change
vs. control; D) on exercise response was different in
Hypoxia versus Normoxia, regression analysis was per-
formed with FiO2 and treadmill speed, as well as their
interaction as independent variables and animal number
as case label. To test for the effect of hypoxia (vs. nor-
moxia) on endothelium-independent but NO-mediated
vasodilatation (SNP), General Linear Model (GLM) –
Repeated Measures were used.
Vascular relaxation responses to the different vasoactive
agents were expressed as percentage of contraction to
U46619. Statistical analysis was performed using SPSS
version 21.0 (IBM) and Prism version 5.0 (Graphpad
Software, Inc., La Jolla, CA). The maximal relaxation
(Emax) and half maximal effective concentration (EC50)
in each experiment were calculated using the GraphPad
Prism version 5 for Windows (Graphpad Software, San
Diego, CA). Statistical analysis of maximal relaxation and
EC50 was performed using nonlinear regression (log (ag-
onist) vs. response).
Statistical significance was accepted at P ≤ 0.05.
Grouped data are presented as mean  SEM.
Results
Effect of chronic exposure to hypoxia on
hemodynamics at rest and during exercise
Exercise up to 4 km h1 produced a significant
increase in heart rate (Fig. 2A) and cardiac index
(Fig. 2B) both in animals raised in normoxia and
hypoxia. Although MAP was slightly, but significantly,
lower in hypoxia-raised piglets as compared to nor-
moxia-raised piglets, the exercise-induced systemic
vasodilatation, as measured by the decrease in SVCi,
was comparable between the two groups, and mini-
mally affected MAP in either the normoxic or the
hypoxic group (Fig. 2C and D).
In the pulmonary circulation, PVCi remained constant
during exercise due to the small vasodilator capacity of
the lung vasculature (Fig. 2F; normoxia, 16  10%;
hypoxia, 3  6%). The increase in LAP during exercise,
in combination with the marked increase in cardiac
index, which caused an increase in the pressure drop
across the pulmonary vasculature, in the face of a con-
stant PVCi, resulted in a progressive increase in PAP with
incremental levels of exercise. This exercise-induced
increase in PAP was similar in both groups (Fig. 2E).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Both at rest, and during incremental exercise, PAP was
significantly higher in hypoxia-exposed piglets as com-
pared to normoxia-exposed piglets (Fig. 2E). PVCi was
significantly lower in animals raised in hypoxia, indicative
for pulmonary vasoconstriction and/or vascular remodel-
ing (Fig. 2F). Thus, exposure to chronic hypoxia in early
life leads to pulmonary hypertension at rest and during
exercise, even following re-exposure to normoxia.
Effect of chronic exposure to hypoxia on
the NO-pathway in the pulmonary
vasculature in vivo
In the systemic circulation in vivo, administration of
incremental dosages of the exogenous NO-donor SNP
resulted in a similar decrease in mean aortic pressure
in resting hypoxia- and normoxia-exposed animals
Figure 2. Changes in systemic and pulmonary hemodynamics during graded treadmill exercise in Normoxia (N = 10, 9  1 day postsurgery) -
and Hypoxia (N = 9, 9  1 day postsurgery and re-exposure to normoxia) exposed piglets. Relation between treadmill speed and (A) heart rate
(HR), (B) cardiac index (CI), (C) mean arterial pressure (MAP), (D) systemic vascular conductance index (SVCi), (E) mean pulmonary arterial
pressure (PAP) and (F) pulmonary vascular conductance index (PVCi). Values are mean  SEM. *P ≤ 0.05 effect of exercise; †P ≤ 0.05 versus
Normoxia.
2018 | Vol. 6 | Iss. 20 | e13889
Page 6
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
Nitric Oxide Pathway in Neonatal Pulmonary Vascular Disease D. P.M. de Wijs-Meijler et al.
(Fig. 3A), while heart rate, cardiac index (CI) and SVCi
did not significantly change in either group (data not
shown). In contrast to the systemic hemodynamic
response, SNP caused a dose-dependent decrease in PAP
only in normoxia-exposed piglets (Fig. 3B). In hypoxia-
exposed piglets, the pulmonary vasodilator response to
SNP was abolished (Fig. 3B), indicative for a reduced
responsiveness of the pulmonary vascular bed to NO.
Administration of the NO-synthase inhibitor LNNA
in vivo increased MAP and decreased SVCi to a similar
extent in normoxia-exposed and hypoxia-exposed piglets,
both at rest and during incremental levels of exercise
(Table 2). This increase in aortic pressure was accompa-
nied by a decrease in CI (Table 2). Similar to the systemic
hemodynamic response, PAP markedly increased after
LNNA administration in both groups (Fig. 4A). This
increase in PAP was the result of extensive pulmonary
vasoconstriction, as evidenced by a marked decrease in
PVCi (Table 2). At rest, the LNNA-induced decrease in
PVCi tended to be smaller in hypoxia-exposed piglets
(Table 2, DPVCi normoxia vs. hypoxia p = 0.09), result-
ing in a trend toward a smaller increase in PAP in hypox-
ia-exposed piglets as compared to normoxia-exposed
piglets (Fig. 3A; DPAP normoxia, +17  3 mmHg;
hypoxia, +12  3 mmHg; p = 0.06). In contrast, the
effect of LNNA on PAP during exercise increased signifi-
cantly more in hypoxia-exposed piglets as compared to
controls (Fig. 4A; FiO2*exercise P = 0.05).
At rest, PDE5 inhibition with EMD360527 resulted in a
decrease in MAP in normoxia-exposed and hypoxia
exposed piglets (Table 2). This decrease in MAP was
accompanied by an EMD360527-induced increase in
SVCi, reaching statistical significance in hypoxia-exposed
piglets only. The effect of PDE5 inhibition during exercise
on MAP was significantly larger in hypoxia-exposed pig-
lets as compared to normoxia-exposed piglets, resulting
in a significantly lower MAP at maximal exercise in
hypoxia-exposed piglets (Table 2). In the pulmonary cir-
culation of normoxia-exposed piglets, PDE5 inhibition
increased PVCi and decreased PAP to a similar extent at
rest and during exercise (Table 2, Fig. 4B). However, in
hypoxia-exposed piglets the EMD360527-induced increase
in PVCi was significantly augmented during graded tread-
mill exercise (Table 2; ΔPVCi rest vs. maximal exercise,
P = 0.05). Consequently, while the decrease in PAP at
rest tended to be smaller, the effect of PDE5 inhibition
during exercise was significantly larger in hypoxia-exposed
as compared to normoxia-exposed piglets (Fig. 4B;
FiO2*exercise P = 0.01). These data suggest an impaired
cGMP production or PDE5 activity in hypoxia-exposed
piglets at rest, which recovers during exercise.
Effect of chronic exposure to hypoxia on
the NO-pathway in isolated pulmonary
small arteries
Six weeks following re-exposure to normoxia and
chronic instrumentation, responses of pulmonary small
arteries were determined in vitro. There were no signifi-
cant differences in concentration-dependent vasodilata-
tion to SNP in precontracted isolated porcine
pulmonary small arteries from either normoxia-exposed
or hypoxia-exposed piglets (Fig. 5A). Also, no differ-
ences in relaxation to 8-bromo-cyclic GMP, were found
in pulmonary small arteries isolated from hypoxia-
exposed piglets as compared to controls (Fig. 5B).
Cumulative concentrations of bradykinin produced a
concentration-dependent vasodilatation up to 100% in
Figure 3. Effect of exogenous NO-donor sodium nitroprusside (SNP) on mean arterial pressure (MAP) and mean pulmonary artery pressure
(PAP) during graded treadmill exercise in normoxia- and hypoxia-exposed piglets. Relation between SNP-dosage and (A) change in mean arterial
pressure (ΔMAP; Normoxia, N = 9; Hypoxia, N = 8), and (B) change in mean pulmonary artery pressure (ΔPAP; Normoxia, N = 10; Hypoxia,
N = 8). Experiments were performed 10  1 days postsurgery in both groups. Values are mean  SEM. *P ≤ 0.05 effect of SNP-dosage;
†P ≤ 0.05 versus Normoxia.
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precontracted isolated porcine pulmonary small arteries
from both normoxia-exposed and hypoxia-exposed piglets
(Fig. 5C). This vasodilator response to bradykinin was
significantly shifted to the right in pulmonary small arter-
ies from hypoxia-exposed piglets as compared to
normoxia-exposed controls (logEC50 normoxia 8.32 
0.09 M; hypoxia 7.82  0.09M; P < 0.05), indicative
for impaired endothelium-dependent vasodilatation in
hypoxia-exposed piglets (Fig. 5C). These findings are in
agreement with the reduced vasoconstriction in the
Figure 4. Effect of drug intervention on mean pulmonary artery pressure (PAP) during graded treadmill exercise in normoxia- and hypoxia-
exposed piglets. Relation between treadmill speed and (A) change in mean pulmonary arterial pressure (ΔPAP) after administration of NO-
synthase inhibitor LNNA (Normoxia, N = 9; Hypoxia, N = 8), and (B) change in mean pulmonary artery pressure (ΔPAP) after administration of
PDE5-inhibitor EMD360527 (normoxia, N = 6; Hypoxia, N = 5). LNNA-experiments were performed 18  1 (normoxia) and 19  1 (hypoxia)
days postsurgery, whereas EMD360527 experiments were performed 16  2 (Normoxia) and 14  1 (Hypoxia) days postsurgery. Values are
mean  SEM. *P ≤ 0.05 effect of exercise; †P ≤ 0.05 versus Normoxia.
Figure 5. Vasodilator effects of different vasoactive agents in isolated pulmonary small arteries preconstricted with U46619 (100 nmol/L) from
normoxia- and hypoxia-exposed piglets. Shown are the concentration-response curves to (A) exogenous NO-donor sodium nitroprusside (SNP;
normoxia, N = 9; hypoxia, N = 8) and (B) 8-bromo-cyclic GMP (Normoxia, N = 8; Hypoxia, N = 8). (C) bradykinin (Normoxia, N = 5; Hypoxia,
N = 8), (D) PDE 5-inhibitor sildenafil (Normoxia, N = 6; Hypoxia, N = 8), Values are mean  SEM. †P ≤ 0.05 versus controls (vs. normoxia).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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pulmonary vasculature in response to LNNA at rest in
hypoxia-exposed piglets in vivo.
In accordance with the smaller pulmonary vasodilator
response in vivo in resting hypoxia-exposed piglets, the
CRC to the PDE5 inhibitor sildenafil was significantly dif-
ferent in precontracted isolated porcine pulmonary small
arteries from hypoxia-exposed piglets as compared to
those from normoxia-exposed piglets (Fig. 5D, logEC50
normoxia 7.67  0.17 M, hypoxia 7.28  0.24 M).
These data are consistent with an impaired basal cGMP
production or a lower PDE5 activity in pulmonary small
arteries from hypoxia-exposed piglets.
Discussion
The present study compared the pulmonary vascular
response of normoxia-exposed control piglets and piglets
with hypoxia-induced pulmonary vascular disease, both
in vivo and in vitro, to determine the functionality of dif-
ferent parts of the NO-cGMP signaling pathway. The
main findings of the present study were that (1) exposure
to chronic hypoxia in early life leads to pulmonary hyper-
tension at rest and during exercise, even following re-ex-
posure to normoxia. (2) the exogenous NO-donor SNP
produced a dose-dependent decrease in PAP in normox-
ia-exposed but not hypoxia-exposed piglets, indicative for
a reduced responsiveness of the pulmonary vascular bed
to NO in this group (3) eNOS inhibition with LNNA
resulted in an increase in PAP that tended to be smaller
at rest, and larger during exercise in hypoxia-exposed
compared to normoxia-exposed piglets. (4) In vivo, the
PDE5 inhibition-induced decrease in PAP tended to be
smaller at rest, while the effect of PDE5 inhibition during
exercise was significantly larger in the pulmonary vascula-
ture of hypoxia-exposed as compared to normoxia-
exposed piglets. (5) In vitro, the vasodilator response to
BK was significantly shifted to the right in hypoxia-
exposed piglets and (6) the vasorelaxant response to the
PDE5 inhibitor sildenafil was significantly blunted in pre-
contracted isolated porcine pulmonary small arteries from
hypoxia-exposed piglets as compared to normoxia-
exposed piglets. However, (7) no impairments in vasore-
laxation to SNP or the NO second messenger, 8-bromo-
cyclic GMP, were found in pulmonary small arteries
isolated from hypoxia-exposed piglets as compared to
controls. The implications of the se findings are discussed
below.
Animal model
Infants suffering from cardiopulmonary disorders associ-
ated with persistent or episodic hypoxia, such as BPD, are
at risk for the development of PVD (including PH).
Unfortunately, these patients often have a poor respon-
siveness to inhaled NO and alternative effective treat-
ments for chronic PH in these patients remain largely
limited. To better understand the pathophysiological
mechanisms and to develop new therapies, several animal
models for neonatal PVD and pulmonary hypertension,
including a neonatal swine model with hypoxia-induced
pulmonary hypertension, have already been established
(Plunkett et al. 1996; Scarborough et al. 1998; Perreault
et al. 2001; Binns-Loveman et al. 2005; Fike et al. 2005,
2015; Ananthakrishnan et al. 2009; Camelo et al. 2012).
Swine lungs share many anatomical, histological, bio-
chemical, and physiological features with human lungs
(Rogers et al. 2008) and the relevance of the developing
pulmonary circulation of neonatal piglets to human
infants has been established already in the early ‘80s
(Haworth and Hislop 1981, 1982). Although alveolar
multiplication occurs faster in piglets (2–4 weeks com-
pared to 3 years in human infants), the morphological
development of pulmonary architecture in swine is com-
parable with humans (Rogers et al. 2008). We recently
developed a neonatal swine model with hypoxia-induced
PH, allowing long-term follow-up for several weeks after
re-exposure to normoxia (de Wijs-Meijler et al. 2017c).
We showed that pulmonary hypertension induced by
chronic hypoxia is transient, as pulmonary artery pressure
was normalized 2–3 weeks after re-exposure to normoxia
particularly in female swine. However, despite normaliza-
tion of PAP, structural and functional changes in the
right ventricle and the lung vasculature (vascular remod-
eling with smooth muscle cell proliferation) persisted
throughout the 6-week study period (de Wijs-Meijler
et al. 2017c). In the present study, we elaborated on these
findings and showed that the structural pulmonary
microvascular changes were accompanied by altered regu-
lation of pulmonary microvascular tone both in vivo and
in vitro. Unfortunately, sample size in the different exper-
imental protocols did not allow to investigate whether sex
affected the vasoreactivity of the pulmonary vasculature.
A limitation of our model is that the flow probe that was
placed around the pulmonary artery in a subset of ani-
mals to measure cardiac output in vivo, caused a signifi-
cant pulmonary artery stenosis that precluded pulmonary
hemodynamic as well as right ventricular structural analy-
ses beyond 3 weeks of re-exposure to normoxia.
The NO-cGMP pathway in neonatal
pulmonary vascular disease at rest
The NO-cGMP signaling pathway is important for the
adjustments in the pulmonary vasculature that accom-
pany the transition from pre- to postnatal life following
birth. There is increasing evidence that alterations in the
2018 | Vol. 6 | Iss. 20 | e13889
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NO-cGMP signaling pathway play an important role in
the pathogenesis of neonatal pulmonary vascular disease,
including PH (Fike et al. 1998, 2004, 2015; Berkenbosch
et al. 2000). In neonatal intensive care units, iNO is used
as rescue therapy for preterm infants with respiratory dis-
ease undergoing ventilation (Berkelhamer et al. 2013b;
Rossor and Greenough 2015; Baczynski et al. 2017). As
perinatal hypoxia impacts the NO-cGMP pathway (Fike
et al. 1998, 2004; Herrera et al. 2010; Blum-Johnston
et al. 2016), and we have previously shown that neonatal
hypoxia-induced pulmonary vascular alterations persist
for several weeks following re-exposure to normoxia (de
Wijs-Meijler et al. 2017c), we investigated the functional-
ity of different parts of this pathway in our model of
neonatal hypoxia-induced PH. Endothelium-dependent
vasodilatation was impaired in isolated pulmonary small
arteries from hypoxia-exposed piglets, as evidenced by a
significant rightward shift of the vasodilator response to
bradykinin. These data are consistent with a study show-
ing that perinatal hypoxia results in an impaired vasodila-
tor response to bradykinin in isolated pulmonary small
arteries of lambs (Blum-Johnston et al. 2016). We have
previously shown that pulmonary vasodilation to bradyki-
nin is largely NO-dependent (de Wijs-Meijler et al.
2017b), suggesting that the reduced response to bradyki-
nin reflects impaired NO signaling. In accordance with
these findings in older swine, preliminary data show that
eNOS inhibition reduced the vasodilator response to bra-
dykinin in vessels from both hypoxia-exposed piglets
(N = 8, logEC50 from 7.82  0.09 mol/L to 7.70 
0.42 mol/L, maximum response from 94  4% to
31  7%, P < 0.05) and control (N = 2, log EC50 from
8.32  0.09 mol/L to 7.29  0.25 mol/L, maximum
response from 91  3% to 32  6%, P < 0.05) and abro-
gated the difference in response to bradykinin between
groups. These data are consistent with our in vivo find-
ings that eNOS inhibition resulted in a smaller increase in
PAP and PVCi at rest in hypoxia exposed piglets as well
as with findings of previous studies in neonatal piglets
with hypoxia-induced PH from other groups. Both Fike
et al. (1998) and Berkenbosch et al. (2000) found an
impaired production of NO, through reduced eNOS pro-
tein expression and/or activity or dysfunction/uncoupling
of eNOS (Fike et al. 2004, 2013, 2015) in swine following
exposure to hypoxia in the early postnatal period. Timing
of hypoxia and/or the animal model used may influence
the effect of hypoxia on the NO-pathway. Thus, perinatal
hypoxia in lambs did not affect the contribution of NO
to bradykinin-induced dilatation (Blum-Johnston et al.
2016).
In addition to this evidence showing an impaired NO-
production in neonatal PH, a recent study by Baczynski
et al. (2017) showed that the positive response rate to
iNO in preterm neonates with acute PH is only 46%, sug-
gesting disruptions in the NO-cGMP pathway more
downstream to eNOS/NO-production which result in an
apparent reduction of the responsiveness to NO. In agree-
ment with findings of other studies (Berkenbosch et al.
2000; Fike et al. 2013), chronic postnatal hypoxia was
associated with a diminished vasodilator responsiveness to
the exogenous NO-donor SNP in vivo in the present
study. In contrast, there were no significant differences in
concentration-dependent vasodilatation to SNP in pre-
contracted isolated porcine pulmonary small arteries from
either normoxia-exposed or hypoxia-exposed piglets. A
limitation of our in vitro study is that the isolated pul-
monary small arteries were used after overnight storage at
4°C, and hence it could be argued that the discrepancy
between the in vivo and in vitro results may originate
from this overnight storage. This is, however, unlikely as
cellular processes that may affect vascular function will be
decelerated at 4°C. Indeed, it has been shown that over-
night storage of middle cerebral arteries does not affect
vascular function to a wide variety of vasoconstrictors
(prostaglandin F2a, UTP), endothelium-independent
(SNP, papaverine) and (partially) endothelium-depen-
dent, receptor- mediated (noradrenaline, histamine), and
endothelium-dependent, receptor-independent eNOS-
mediated (L-arginine) vasodilators (Laing et al. 1995).
Furthermore, overnight storage is a standard procedure in
our laboratory, endothelial function as assessed with sub-
stance P was preserved in the vessel segments from both
normoxia and hypoxia-exposed animals, and we have pre-
viously shown clear differences between pulmonary small
arteries from swine with pulmonary hypertension sec-
ondary to pulmonary vein banding and healthy controls
that were performed within a week of killing, and that
were consistent with in vivo observations (van Duin et al.
2018).
An alternative explanation for the discrepancy between
our in vivo and in vitro results could be that the response
of one segment of the pulmonary vasculature, that is the
pulmonary small arteries, in vitro does not completely
reflect the response of the intact pulmonary vasculature
with vessels from different sizes contributing to overall
pulmonary vascular resistance responses. However, it is
most likely that the discrepancy between in vivo and
in vitro findings is explained by the length of re-exposure
to normoxia. In vivo experiments were performed 1–-
3 weeks after re-exposure to normoxia, whereas piglets
were killed after 4–6 weeks. Indeed, pulmonary small
arteries from lambs exposed to prenatal hypoxia, that
were maintained in normoxia for approximately 3 weeks
following delivery showed a reduced responsiveness to
SNP (Herrera et al. 2010). This reduced responsiveness to
SNP was accompanied by upregulation of PDE5.
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Conversely, in our study, a reduced pulmonary vasodila-
tor response to PDE5 inhibition in hypoxia-exposed pig-
lets as compared to normoxia-exposed control piglets was
present both in vivo and in vitro, which is consistent with a
reduced cGMP production in piglets with hypoxia-induced
pulmonary vascular disease. The effectors of cGMP-
mediated vasodilatation are the BKCa channels. These BKCa
channels are upregulated in pulmonary vascular smooth
muscle cells by exposure to hypoxia in vitro (Resnik et al.
2006), and following prenatal hypoxia and postnatal
normoxia in vivo (Herrera et al. 2010). However, their
contribution to bradykinin-induced vasodilatation in vitro
following perinatal hypoxia was reduced (Blum-Johnston
et al. 2016). Altogether, evidence from the literature as
well as the present study suggests that the impaired
endothelium-dependent vasodilatation in piglets with
hypoxia-induced PH in the first 3 weeks after re-exposure
to normoxia is due to a reduced responsiveness to NO,
probably caused by altered sensitivity and/or activity of
sGC, resulting is an impaired cGMP production, which
may (partially) be compensated by an increased expression
of BKCa channels. Our findings are consistent with previous
in vivo and in vitro studies which investigated the effect
of sGC activators and stimulators in acute and chronic
hypoxia. Lundgren et al. (2012) showed that sGC stimula-
tion completely reversed the pulmonary vasoconstrictor
response to acute hypoxia in pigs. Weissmann et al. (2009)
also found a dose-dependent attenuation of acute pul-
monary hypoxic vasoconstriction in isolated perfused
mouse lung upon sGC stimulation. Furthermore, they
found that administration of the sGC activator HMR1766
during exposure to chronic hypoxia reduced pulmonary
hypertension, as well as right ventricular hypertrophy and
structural remodeling of the lung vasculature (Weissmann
et al. 2009). In addition, sGC stimulation and/or activation
have been shown to inhibit or reverse the development of
chronic hypoxic pulmonary hypertension in neonatal
(Deruelle et al. 2006) and adult rats (Thorsen et al. 2010)
and adult mice (Dumitrascu et al. 2006). Our study
adds important information to these previous studies by
showing that alterations in the NO-pathway in a neona-
tal porcine model are still present several weeks after
re-exposure to normoxia, and we speculate that this is
due to a decrease in sGC sensitivity/activity.
The NO-cGMP pathway in neonatal
pulmonary vascular disease during exercise
Exercise resulted in an increase in pulmonary artery pres-
sure in both normoxia and hypoxia-exposed swine. Such
exercise-induced increase in pulmonary artery pressure is
generally observed in quadrupeds, and much less in
humans (Merkus et al. 2008). The main difference
between the lungs of quadrupeds and humans is that the
lungs of quadrupeds are located for a large part above
heart level and that the entire lung is already perfused
under resting conditions, whereas the large lower lung
lobes of humans are at heart level, and the upper lobes
are generally minimally perfused at rest. This means that
recruitment of the hypo-perfused lung lobes during exer-
cise as occurs in humans is not possible in swine, result-
ing in an increase in pulmonary artery pressure with an
increase in cardiac output (Merkus et al. 2008).
It is well known that the NO-cGMP signaling pathway
plays an important role in exercise-induced pulmonary
vasodilatation (Merkus et al. 2008). Given the exercise
intolerance in patients with pulmonary vascular disease, it
is of interest to investigate the functionality of this path-
way during exercise. In the present study, we are the first
to investigate the effect of exercise on NO-cGMP signal-
ing in a model for neonatal hypoxia-induced pulmonary
vascular disease.
In contrast to the smaller vasoconstrictor response of the
pulmonary vasculature to NO-synthase inhibition at rest,
the effect of LNNA on PAP during exercise tended to be
larger in hypoxia-exposed piglets as compared to controls.
Interestingly, the effect of PDE5 inhibition during
exercise was significantly larger in the pulmonary vascu-
lature of hypoxia-exposed as compared to normoxia-
exposed piglets, whereas it tended to be smaller at rest.
This apparent discrepancy between the findings at rest
and during exercise suggests a normalization of cGMP
production during exercise. Given the impaired sGC
activity, this normalization may involve membrane-
bound or particulate guanylyl cyclase (pGC). The activ-
ity of pGC can be stimulated by natriuretic peptides
(ANP and BNP) (Kobialka and Gorczyca 2000). It is
Figure 6. Effect of mean pulmonary arterial pressure (PA) on the
pulmonary vasodilator effect of PDE5 inhibition with EMD360527.
A significant correlation between PAP and the pulmonary
vasodilator effect (ΔPAP) of PDE5 inhibition (r2 = 0.82) is shown.
Values are mean  SEM. *P ≤ 0.05 correlation between PAP and
ΔPAP.
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possible that the significant increase in PAP during
incremental exercise causes secretion of natriuretic pep-
tides by cardiomyocytes in response to cardiac stretch
(Wong et al. 2017), and thus pGC activation. In sup-
port of this hypothesis, PAP and the pulmonary
vasodilator effect of PDE5 inhibition were highly corre-
lated (r2 = 0.82; P < 0.05; Fig. 6). In hypoxia-exposed
piglets, PAP is significantly higher as compared to nor-
moxia-exposed piglets, resulting in higher natriuretic
peptide levels and, consequently, higher pGC activity.
Whether higher natriuretic peptide levels are indeed
present in this animal model and act to enhance cGMP
production and thereby increase the vasodilator
response to PDE5 inhibition, should be tested in future
experiments.
Conclusion and Implications
In conclusion, hypoxia-induced PH is accompanied by
impaired endothelium-dependent vasodilatation in the
pulmonary vasculature. In addition to evidence for an
impaired NO-production in neonatal hypoxia-induced
PH, through a reduced eNOS protein expression and/or
activity (Fike et al. 1998; Berkenbosch et al. 2000) or dys-
function/uncoupling of eNOS (Fike et al. 2004, 2013,
2015), the present study provides evidence that there are
disruptions in the NO-cGMP pathway more downstream
to eNOS/NO. Thus, in our model for neonatal PH the
impaired endothelium-dependent vasodilatation was
accompanied by a reduced responsiveness to NO in vivo,
which may be caused by altered sensitivity and/or activity
of sGC.
Our findings in a newborn animal model for neonatal
pulmonary vascular disease suggests that sGC stimulators/
activators could be of benefit as a novel treatment strategy
to stop or even reverse neonatal pulmonary vascular dis-
ease and/or PH, especially since the use of iNO for pre-
term infants with respiratory failure is currently under
debate (Barrington and Finer 2007; Askie et al. 2011; Cole
et al. 2011; Donohue et al. 2011).
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